Target type: biologicalprocess
Any process that stops, prevents, or reduces the frequency, rate or extent of macrophage activation. [GOC:jl]
Negative regulation of macrophage activation is a crucial process in controlling inflammation and immune responses. Macrophages, phagocytic cells found in various tissues, play a pivotal role in innate immunity, responding to pathogens and tissue damage. However, uncontrolled macrophage activation can lead to chronic inflammation and tissue destruction. Therefore, mechanisms exist to tightly regulate macrophage activation. These mechanisms involve a complex interplay of signaling pathways, transcription factors, and cytokines, ultimately modulating macrophage phenotype and function.
One key aspect of negative regulation is the suppression of pro-inflammatory signaling pathways. For instance, inhibitory receptors like PD-1 and CTLA-4 can engage with their ligands on immune cells, leading to downregulation of signaling pathways triggered by Toll-like receptors (TLRs) and other activating receptors. This suppression reduces the production of pro-inflammatory cytokines, such as TNF-α, IL-6, and IL-1β, thus dampening macrophage activation.
Furthermore, anti-inflammatory cytokines, such as IL-10 and TGF-β, play a vital role in regulating macrophage activation. These cytokines can induce a shift in macrophage phenotype towards an anti-inflammatory or regulatory state. IL-10, for example, inhibits the production of pro-inflammatory cytokines and promotes the expression of anti-inflammatory molecules, while TGF-β can induce the differentiation of macrophages into regulatory M2 macrophages, which promote tissue repair and immune suppression.
Another important mechanism is the induction of negative feedback loops. Activated macrophages can produce anti-inflammatory mediators that suppress their own activation. For instance, IL-10 can act in an autocrine manner to inhibit its own production, preventing excessive inflammation.
Additionally, epigenetic modifications, such as histone methylation and acetylation, can influence the expression of genes involved in macrophage activation. These modifications can modulate the accessibility of DNA to transcription factors, ultimately controlling the production of pro- and anti-inflammatory cytokines.
Finally, the immune microenvironment plays a crucial role in shaping macrophage activation. Cells like regulatory T cells (Tregs) and dendritic cells (DCs) can release factors that modulate macrophage function. Tregs, for example, produce IL-10 and other suppressive cytokines that dampen macrophage activation, while DCs can present antigens in a way that promotes immune tolerance and limits inflammation.
In conclusion, negative regulation of macrophage activation is a multi-faceted process involving various signaling pathways, cytokines, transcription factors, and epigenetic modifications. This intricate network of regulatory mechanisms ensures appropriate immune responses, preventing excessive inflammation and maintaining tissue homeostasis.'
"
Protein | Definition | Taxonomy |
---|---|---|
Oxysterols receptor LXR-alpha | An oxysterols receptor LXR-alpha that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q13133] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
1-deoxynojirimycin | 1-deoxy-nojirimycin: structure in first source duvoglustat : An optically active form of 2-(hydroxymethyl)piperidine-3,4,5-triol having 2R,3R,4R,5S-configuration. | 2-(hydroxymethyl)piperidine-3,4,5-triol; piperidine alkaloid | anti-HIV agent; anti-obesity agent; bacterial metabolite; EC 3.2.1.20 (alpha-glucosidase) inhibitor; hepatoprotective agent; hypoglycemic agent; plant metabolite |
betulinic acid | hydroxy monocarboxylic acid; pentacyclic triterpenoid | anti-HIV agent; anti-inflammatory agent; antimalarial; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; plant metabolite | |
25-hydroxycholesterol | 25-hydroxy steroid; oxysterol | human metabolite | |
bexarotene | benzoic acids; naphthalenes; retinoid | antineoplastic agent | |
3 beta-hydroxy-delta 5-cholenic acid | steroid | ||
podocarpic acid | podocarpic acid : An abietane diterpenoid lacking the isopropyl substituent with an aromatic C-ring and a hydroxy group at the 12-position. podocarpic acid: structure | abietane diterpenoid | |
(20s)-20-hydroxycholesterol | 20-hydroxycholesterol : An oxysterol that is cholesterol substituted by a hydroxy group at position 20. 20-hydroxycholesterol: RN given refers to (20S)-isomer | 20-hydroxy steroid; 3beta-hydroxy-Delta(5)-steroid; oxysterol | human metabolite; mouse metabolite |
24-hydroxycholesterol | (24S)-24-hydroxycholesterol : A 24-hydroxycholesterol that has S configuration at position 24. It is the major metabolic breakdown product of cholesterol in the brain. | 24-hydroxycholesterol | biomarker; human blood serum metabolite; mouse metabolite |
27-hydroxycholesterol | (25R)-cholest-5-ene-3beta,26-diol : A 26-hydroxycholesterol in which the 25-position has R-configuration. | 26-hydroxycholesterol | apoptosis inducer; human metabolite; mouse metabolite; neuroprotective agent |
cyanidin | cyanidin cation : An anthocyanidin cation that is flavylium substituted at positions 3, 3', 4', 5 and 7 by hydroxy groups. cyanidin: RN given refers to parent cpd; structure | 5-hydroxyanthocyanidin | antioxidant; metabolite; neuroprotective agent |
(22r)-22-hydroxycholesterol | (22R)-22-hydroxycholesterol : An oxysterol that is the 22R-hydroxy derivative of cholesterol. | 22-hydroxy steroid; 3beta-hydroxy-Delta(5)-steroid; oxysterol | |
22s-hydroxycholesterol | (22S)-22-hydroxycholesterol : An oxysterol that is the 22S-hydroxy derivative of cholesterol. | 22-hydroxy steroid; 3beta-hydroxy-Delta(5)-steroid; oxysterol | |
gw 3965 | GW 3965: a liver X receptor ligand | diarylmethane | |
t0901317 | T0901317: an LXRalpha and LXRbeta agonist | ||
alitretinoin | Alitretinoin: A retinoid that is used for the treatment of chronic hand ECZEMA unresponsive to topical CORTICOSTEROIDS. It is also used to treat cutaneous lesions associated with AIDS-related KAPOSI SARCOMA. | retinoic acid | antineoplastic agent; keratolytic drug; metabolite; retinoid X receptor agonist |
24,25-epoxycholesterol | 24,25-epoxycholesterol: Rn given refers to (3alpha,5beta)-isomer; structure given in first source 24(S),25-epoxycholesterol : A 3beta-hydroxy-Delta(5)-steroid that is desmosterol in which the double bond at position 24-25 has been oxidised to the corresponding epoxide (the 24S diastereoisomer). It is an oxysterol agonist of the liver X receptor. | 3beta-hydroxy-Delta(5)-steroid; cholestanoid; epoxy steroid | liver X receptor agonist |
genistein | 7-hydroxyisoflavones | antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor | |
piericidin a | piericidin A : A member of the class of monohydroxypyridines that acts as an irreversible mitochondrial Complex I inhibitor that strongly associates with ubiquinone binding sites in both mitochondrial and bacterial forms of NADH:ubiquinone oxidoreductase piericidin A: pyridine-substituted fatty alcohol antibiotic; minor descriptor (75-85); on-line & Index Medicus search ANTIBIOTICS (75-85); RN given refers to (S-(R*,R*-(all-E)))-isomer | aromatic ether; methylpyridines; monohydroxypyridine; secondary allylic alcohol | antimicrobial agent; bacterial metabolite; EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitor; mitochondrial respiratory-chain inhibitor |
pregna-4,17-diene-3,16-dione | pregna-4,17-diene-3,16-dione: steroid from guggulu extract; RN & N1 from C1 Form index; RN given refers to cpd without isomeric designation; structure in first source; antagonist of farnesoid X receptor | 3-hydroxy steroid | androgen |
acanthoic acid | acanthoic acid: from root bark of Acanthopanax koreanum; structure given in first source | ||
3-chloro-4-(3-(7-propyl-3-trifluoromethyl-6-benzisoxazolyl)propylthio)phenylacetic acid | |||
riccardin c | riccardin C: isolated from liverworts; functions as a liver X receptor (LXR)alpha agonist and an LXRbeta antagonist; structure in first source | ||
bms 687453 | |||
way 252623 | 2-(2-chloro-4-fluorobenzyl)-3-(4-fluorophenyl)-7-(trifluoromethyl)-2H-indazole: a partial LXR agonist | ||
cholenic acid dimethylamide | cholenic acid dimethylamide: binds LXRalpha receptor; structure in first source | ||
glucopiericidin a | glucopiericidin A: from Streptomyces pactum S48727 as co-metabolite of piericidin A(1); structure given in first source; glycoside antibiotic | ||
gsk4112 | GSK4112: a Rev-erbalpha agonist; structure in first source | ||
sr9009 | |||
sr9011 | SR9011: a REV-ERB agonist; structure in first source | ||
sr9238 | SR9238: liver-selective LXR inverse agonist that suppresses hepatic steatosis; structure in first source |